(March 21, 2025) – On Friday, March 14, the U.S. Food and Drug Administration released
Disruptions in Availability of Hemodialysis Bloodlines – Letter to Health Care Providers | FDA to communicate supplier issues with hemodialysis bloodlines. The letter states that the supply delays are expected to extend into early fall of 2025, and they recommend conservation. They also provide guidance on reporting any supply chain challenges to the FDA.
--
Larry Van Der Wege